Welcome to our dedicated page for Altamira Therapeutics news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics stock.
Altamira Therapeutics Ltd. (historically Nasdaq: CYTO) generates news primarily around its RNA delivery platforms, legacy therapeutic assets, and capital markets activity. Company announcements describe ongoing development of its peptide-based nanoparticle technologies OligoPhore and SemaPhore for efficient RNA delivery to extrahepatic tissues, along with preclinical progress in its flagship siRNA programs AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis.
News items frequently cover business updates and financial results, where Altamira outlines its strategic repositioning around RNA delivery, reports on research milestones, and discusses collaborations with biotech and pharma partners. Press releases have highlighted independent preclinical publications using its SemaPhore platform in oncology and inflammatory disease models, as well as internal advances in nanoparticle formulation and process development.
Altamira-related news also includes developments from its associated company Altamira Medica AG and the commercial-stage nasal spray Bentrio. Announcements have detailed license and distribution agreements for Bentrio in regions such as East and South East Asia and Scandinavia, expansion of partner territories, and clinical data supporting its use in allergic rhinitis and protection against airborne particles. Additional releases have addressed topics like Bentrio’s suitability for athletes based on analytical testing for substances on the World Anti-Doping Agency list.
Capital markets and listing updates form another important category of news. The company has issued releases on public offerings of common shares and warrants, use of proceeds for working capital and research, and its transition from the Nasdaq Capital Market to the OTCQB marketplace following a Nasdaq delisting decision related to the minimum bid price rule. Investors following CYTO can use this news stream to monitor scientific progress, partnering activity, commercialization steps for Bentrio, and changes in trading venue or financing transactions.
Altamira Therapeutics (Nasdaq: CYTO) announced that its Bentrio® nasal spray for allergic rhinitis has been successfully tested for the absence of over 230 prohibited substances listed by the World Anti-Doping Agency (WADA). This confirmation enhances Bentrio's suitability for athletes who need to comply with anti-doping regulations while protecting themselves against airborne allergens or particles.
The drug-free and preservative-free nasal spray forms a protective barrier on the nasal mucosa, making it inherently suitable for athletes. The rigorous screening by a leading anti-doping laboratory further validates its compliance with anti-doping regulations, addressing the challenges athletes face in managing allergies without risking positive doping test results.
Altamira Therapeutics announced significant enhancement of immune checkpoint inhibition therapy using Zbtb46 mRNA delivered with SemaPhore Nanoparticles in animal tumor models. Key findings published in Nature Immunology include:
1. Zbtb46 mRNA nanoparticles significantly reduced tumor growth (p<0.0001).
2. Combination with anti-PD1 showed synergistic control of tumor growth and long-term complete remission in many cases.
3. Treatment may help more solid tumor patients respond to anti-PD1 therapies.
4. Zbtb46 expression boosted tumor vessel normalization and enhanced antitumor immunity.
5. Results highlight potential of SemaPhore platform for delivering mRNA therapeutics to non-hepatic tissues.
Altamira Therapeutics (Nasdaq:CYTO) has announced the publication of a preclinical study demonstrating effective treatment of abdominal aortic aneurysm (AAA) using their SemaPhore™ nanoparticles to deliver SOD2 mRNA. The study, conducted by researchers from Washington University and the University of South Florida, showed significant reduction in aorta dilation (p<0.05), delayed rupture, and highly significant improvement in survival rates (p<0.01) compared to untreated controls in an AAA mouse model.
The treatment approach targets oxidative stress by boosting mitochondrial SOD2 expression, reducing levels of reactive oxygen species (ROS). This nanotherapeutic mRNA delivery method may have potential applications in managing small AAAs and preventing ruptures, which are often life-threatening.
Altamira Therapeutics, under the stock ticker CYTO, has highlighted a newly published review supporting the use of betahistine for managing residual dizziness in benign paroxysmal positional vertigo (BPPV) patients. The review, appearing in Frontiers in Neurology, suggests that betahistine, which is commonly used outside the US, can significantly reduce dizziness following physical repositioning procedures. Altamira is developing a nasal spray formulation called AM-125, which offers higher bioavailability than oral betahistine. The company aims to partner or divest AM-125 as it pivots towards RNA delivery technology. BPPV is the most common type of vertigo, affecting 17-42% of diagnosed vertigo cases and costing the US healthcare system around $2 billion annually.
Altamira Therapeutics provided a business update, highlighting significant improvements in RNA nanoparticle stability, which are now stable in liquid form at 4°C for at least three weeks and can withstand shaking stress.
The company is pursuing partnerships for its AM-125 nasal spray for vertigo and other CNS disorders. AM-125 has shown promising Phase 2 trial results in Europe and potential for multiple CNS applications.
Altamira is streamlining its corporate structure, merging subsidiaries and switching its financial reporting from Swiss Francs to US Dollars to better align with its strategic focus and investor base.
Altamira Therapeutics announced the dissemination of positive results from its NASAR clinical trial for Bentrio nasal spray in treating seasonal allergic rhinitis (SAR). The trial's results, published in the Allergy journal's social media channels, showed significant efficacy and safety. The study, involving 100 patients in Australia, met its primary endpoint by significantly reducing the mean daily reflective Total Nasal Symptom Score (rTNSS) compared to saline (p = 0.013). Secondary endpoints also showed significant improvements in quality of life and global efficacy ratings (p < 0.001). Altamira expects Bentrio's sales to grow significantly with planned launches in new markets in 2024.
Altamira Therapeutics has filed a provisional patent application for OligoPhore nanoparticles with siRNA targeting p65 protein for the treatment of cancer and inflammation. The company aims to expand its IP portfolio focusing on RNA delivery technology, particularly for rheumatoid arthritis. The innovative approach utilizes siRNA to silence p65, a key protein involved in cancer and inflammatory diseases, including rheumatoid arthritis. Altamira's AM-411 program demonstrates promising results by delivering siRNA to inflamed tissues, offering potent treatment effects with reduced side effects and treatment resistance risks. Rheumatoid arthritis affects millions globally, with no cure currently available, making the development of effective treatments crucial.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Altamira Therapeutics (CYTO)?
What is the market cap of Altamira Therapeutics (CYTO)?
